AMR.Solutions

Search
Close this search box.

REVAMP, a pull incentive in the US: Time to make it happen!

Dear All: I previously wrote about the nascent REVAMP legislation that would create a Pull incentive in the US market. With everybody back from the July 4th holiday, the goal for this week is to get REVAMP into position to be offered as an amendment at the House Energy & Commerce Committee’s PAHPA mark-up (expected next week). To that end, it’s now your turn to be an active citizen. Can you take action on either of the following ideas?

 

  1. Building support among members of the House Energy & Commerce Committee
    • Below my signature, you will find a list of healthcare staffers for Members of the Energy & Commerce Committee. As is relevant to you, now is the time for you to write to any (or all!) of these offices to urge their co-sponsorship of HR 6294 (REVAMP). 
    • The key Democratic offices who understand the crisis in AMR and seem most inclined to support are Eshoo, Peters, Butterfield, DeGette, Ruiz, and Lujan.
    • All Republican offices are potential strong supporters.
    • A personalized note to the named staffer is the best approach. As a reminder, here is a summary of REVAMP.
  2. Signing (and encourage signing of) the S-FAR/IDSA Sign-on Letter: Deadline Tuesday July 10
    • The Stakeholder Forum on Antimicrobial Resistance (S-FAR, https://s-far.org/; link no longer working as of March 2022) partnership through the IDSA and Antimicrobial Innovation Alliance are circulating this sign-on letter to Energy & Commerce leadership urging them to support the bill and include it in PAHPA Reauthorization. Please contact Collin McGoodwin (cmcgoodwin@idsociety.org) by close of business this Tuesday, July 10, if your organization would like to sign onto the letter. 
    • The following groups have already signed the current letter: National Association of Pediatric Nurse Practitioners, the March of Dimes, the C. Diff Foundation, the Society of Critical Care Medicine, the American Association of Bovine Practitioners, the Alliance for the Prudent Use of Antibiotics, the Emory Antibiotic Resistance Center, Spero Therapeutics, Making A Difference in Infectious Diseases, and Accelerate Diagnostics. 
    • The following groups previously signed a letter urging a market incentive on PAHPA and now would be a good time for them to again send a message. If you have contacts at the following societies, please reach out and encourage them to add their support to the bill: AdvaMedDx, the Alliance for Aging Research, the American Society for Microbiology, the American Thoracic Society, the Antimicrobials Working Group, Becton-Dickinson, and the Trust for America’s Health.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Membership of the House Energy & Commerce Committee
BOLD: members are on HEALTH Subcommittee
Marked with asterisk: especially key members for outreach

Members (Republicans): Staff
Greg Walden (R-OR) – Chairman: nolan.ahern@mail.house.gov
Joe Barton (R-TX): gable.brady@mail.house.gov
John Shimkus (R-IL): brian.looser@mail.house.gov
Michael Burgess (R-TX): edward.kim2@mail.house.gov
Marsha Blackburn (R-TN): Meghan.stringer@mail.house.gov
Fred Upton (R-MI): mark.ratner@mail.house.gov
Steve Scalise (R-LA): greg.watson@mail.house.gov
Robert Latta (R-OH): rachel.schwegman@mail.house.gov
Cathy McMorris Rodgers (R-WA): jerry.white@mail.house.gov
Gregg Harper (R-MS): elizabeth.joseph@mail.house.gov
Leonard Lance (R-NJ): robert.butora@mail.house.gov
Brett Guthrie (R-KY): sophie.trainor@mail.house.gov
Pete Olson (R-TX): kevin.hartley@mail.house.gov
David McKinley (R-WV): christopher.buki@mail.house.gov
Adam Kinzinger (R-IL): Sarah.czufin@mail.house.gov
Morgan Griffith (R-VA): kristin.seum@mail.house.gov
Gus Bilirakis (R-FL): thomas.power@mail.house.gov
Bill Johnson (R-OH): Kelli.ripp@mail.house.gov
Billy Long (R-MO): tanner.warbinton@mail.house.gov
Larry Bucshon (R-IN): sarah.killeen@mail.house.gov
Bill Flores (R-TX): christopher.taylor@mail.house.gov
Susan Brooks (R-IN): Kristina.dunklin@mail.house.gov
Markwayne Mullin (R-OK): taylor.hittle@mail.house.gov
Richard Hudson (R-NC): preston.bell@mail.house.gov
Chris Collins (R-NY): Charlotte.pineda@mail.house.gov
Kevin Cramer (R-ND): bree.vculek@mail.house.gov
Buddy Carter (R-GA): Olivia.dickey@mail.house.gov
Ryan Costello (R-PA): Hannah.anderson@mail.house.gov
Tim Walberg (R-MI): Joanna.brown@mail.house.gov
Mimi Walters (R-CA): casey.fitzpatrick@mail.house.gov
Jeff Duncan (R-SC): addie.patterson@mail.house.gov

Members (Democrats): Staff
Frank Pallone (D-NJ): roberto.sada@mail.house.gov
Bobby Rush (D-IL): yardly.pollas@mail.house.gov
*Anna Eshoo (D-CA): rachel.fybel@mail.house.gov
Eliot Engel (D-NY): hannah.aiken@mail.house.gov
*Gene Green (D-TX): sergio.espinosa@mail.house.gov
*Diana DeGette (D-CO): michelle.greenhalgh@mail.house.gov
*Michael Doyle (D-PA): kate.werley@mail.house.gov
*G.K. Butterfield (D-NC): dennis.sills@mail.house.gov
*Doris Matsui (D-CA): megan.herber@mail.house.gov
Kathy Castor (D-FL): elizabeth.brown@mail.house.gov
Jerry McNerney (D-CA): svetlana.matt@mail.house.gov
*Ben Ray Lujan (D-NM): kimberly.espinosa@mail.house.gov
*Paul Tonko (D-NY): jeff.morgan@mail.house.gov
*John Yarmuth (D-KY): zack.marshall@mail.house.gov
*Yvette Clarke (D-NY): kwamme.anderson@mail.house.gov
*David Loebsack (D-IA): Katie.Murray@mail.house.gov
Kurt Schrader (D-OR): stephen.holland@mail.house.gov
Joseph Kennedy (D-MA): sarah.curtis@mail.house.gov
Tony Cárdenas (D-CA): jacqueline.usyk@mail.house.gov
*Raul Ruiz (D-CA): erin.doty@mail.house.gov
Debbie Dingell (D-MI): greg.sunstrum@mail.house.gov
*Scott Peters (D-CA): anais.borja@mail.house.gov

Upcoming meetings of interest to the AMR community:

  • 22-27 Jul 2018 (Bryant University, Smithfield, RI): Gordon Research Conference on Drug Resistance for Cancer, Infectious Disease and Agriculture
  • 7-8 Aug 2018: A pair of FDA Advisory Committees:
  • 21-22 Aug 2018 (FDA White Oak Campus, Silver Spring, MD): workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections”. Meeting notice is here.
  • 21-22 Aug 2018 (Rockville, MD): NIAID-NINDS-DTRA workshop entitled “Infectious Disease in The CNS and Therapeutic Strategies to Cross the Blood-Brain Barrier”
  • 21-23 Aug 2018 (Cardiff, UK): BSAC Standardized Susceptibility Testing Residential Workshop. Register here.
  • [Don’t miss this one!] 4-7 Sep 2018 ESCMID-ASM Conference (#3) on Drug Development for AMR (Lisbon, Portugal). Full program is now posted.
  • 24-28 Sep 2018 (Big Sky, Montana): MSG-ERC (Mycoses Study Group) Biennal meeting
  • 3-7 Oct 2018 (San Francisco): ID Week
  • 6-14 Oct 2018 International Course on Antibiotics and Resistance (ICARe, Les Pensières, Annecy, France) 
  • 26 Oct 2018 (London): EMA information day for SMEs: “Regulatory toolbox for medicines and combined devices developers”. Here is the current agenda. Webcast will be available. More details from sme@ema.europa.eu.
  • 7-9 Nov 2018 (Seville, Spain): Better Methods for Clinical Studies in Infectious Diseases and Clinical Microbiology: A Hands-on Workshop

Dear All,
 
The IDWeek 2024 program committee is again seeking programs on novel antimicrobial agents and novel diagnostics for presentation in pipeline sessions! Here’s what is sought:

  • “Industry partners are invited to submit antimicrobials that are in preclinical stages of development (Phase II and III preferred) or recently approved after January 2024.
  • “The pipeline sessions will include antibacterials, antifungals, and antivirals (excluding COVID-19 and HIV).
  • “The committee also invites companies developing novel diagnostic technologies with a minimum of some preliminary proof of concept data to submit.” 

This is a great opportunity to tell the story of your development project! The deadline to submit is Wednesday, June 26 via the application portal. Any questions should be directed to program@idsociety.org. Please share this email with anyone you think might be interested in applying!
 
In addition, I’ll also note that those with a more general story to tell should look at the BugHub Stage (and the Global BugHub stage). Both BugHub variants seek “presentations that touch on your experience of working in infectious diseases and presentations that ultimately lead to a greater understanding of our diverse field” via a TED Talk-esque speech about your work. The deadline for applications is 26 June, the same as for the pipeline sessions.

I look forward to seeing you there! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Operating Partner, Advent Life Sciences. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://amr.solutions/blog/. All opinions are my own.

John’s Top Recurring Meetings

Virtual meetings are easy to attend, but regular attendance at annual in-person events is the key to building your network and gaining deeper insight. My personal favorites for such in-person meetings are below. Of particular value for developers are the AMR Conference and the ASM-ESCMID conference. Hope to see you there!

  • 27-30 April 2024 (Barcelona, Spain): 34th ECCMID, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. Go here for details. 
  • 17-20 Sep 2024 (Porto, Portugal): ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Go here for the meeting’s general website. You can’t register (yet) for the 2024 event, but save the date!
  • 16-20 Oct 2024 (Los Angeles, USA): IDWeek 2024, the annual meeting of the Infectious Diseases Society of America. Save the date! More details to come!
  • 25-26 February 2025 (Basel, Switzerland): The 9th AMR Conference 2025. Go here to register! 

Upcoming meetings of interest to the AMR community:

  • [NEW]  9 Apr 2024 (virtual, 830a-10a ET): GARDP’s next REVIVE webinar entitled “Progressing a discovery project – Criteria and challenges.” Register here.
  • [NEW] 9 Apr 2024 (virtual, 10a-1130a ET): CDC webinar “Impacts of Antimicrobial Resistance on Cancer Care.” Click here for details and to register.
  • 10-11 Apr 2024 (virtual): Sepsis Alliance AMR Conference, a 2-day conference focused on “Practical technologies to manage sepsis and counteract the expanding challenge of antimicrobial resistance.” Go here for details and to register.
  • 26 Apr 2024 (Barcelona, Spain): ESCMID workshop entitled “Using Data Science and Machine Learning for Infection Science: A Hands-on Introduction.” Click here to register or here for more details. 
  • 27-30 April 2024 (Barcelona, Spain): 34th ECCMID, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases. See Recurring Meetings list, above.
  • 26-31 May 2024 (Montreal, Canada): EDAR7, the McGill AMR Centre’s 7th edition of their Environmental Dimension of Antimicrobial Resistance conference. Go here for details; final abstract deadline is 21 Dec 2023.
  • 28-29 May 2024 (in person, Uppsala, Sweden): Uppsala Antibiotic Days, a broad-ranging 2-day program hosted by the Uppsala Antibiotic Center. Go here for details and to register.
  • [NEW] 30-31 May 2024 (face-to-face in Rockville, Maryland as well as online, 8.30-5.30p ET on 30 May, 9-2.40p on 31 May): NIAID-sponsored workshop entitled “Towards realizing the promise of adjunctive immune therapy for invasive fungal infections”. The agenda covers host immunity to invasive fungal infections, immune modulators in the context of fungal infections; and strategies for testing immune modulators as adjunctive therapy. Go here for more details and to register.
  • 9-13 June 2024 (in person, Ascona, Switzerland): “New Approaches to Combat Antibiotic-Resistant Bacteria, 2nd Edition” is a Sunday-Thursday residential workshop focused on the deep biology of AMR. Sponsored by NCCR AntiResist (a Swiss National Science Foundation consortium), the scientific program has the feel of a Gordon Conference. Space is limited, so you are encouraged to apply promptly — go here for details.
  • 13-17 June 2024 (Atlanta, Georgia): ASM Microbe, the annual meeting of the American Society for Microbiology. You can’t register yet, but you can go here for general details.
  • 17-20 Sep 2024 (Porto, Portugal): ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. See Recurring Meetings list, above.
  • 16-20 Oct 2024 (Los Angeles, USA): IDWeek 2024, the annual meeting of the Infectious Diseases Society of America. See Recurring Meetings list, above. 
  • 19-27 Oct 2024 (Annecy, France, residential in-person program): ICARe (Interdisciplinary Course on Antibiotics and Resistance). Now in its 8th year, Patrice Courvalin directs the program with the support of an all-star scientific committee and faculty. The resulting soup-to-nuts training covers all aspects of antimicrobials, is very intense, and routinely gets rave reviews! Seating is limited, so mark your calendars now if you are interested. Applications open in March 2024 — go here for more details.
  • 4-5 Dec 2024 (in person, Washington, DC): “Fungal Dx 2024: Fungal Diagnostics in Clinical Practice” is a 2-day in-person workshop organized by ISHAM‘s Fungal Diagnostics Working Group. The program and registration links are available at https://fungaldx.com/; the agenda is comprehensive and features an all-star global list of speakers.

Share

More Newsletters

48,015 → 0: Antibacterial discovery is hard. Really, really hard.

Dear All (and with thanks to Patricia Bradford for co-authoring this newsletter), When you are seeking novelty, antibacterial discovery is hard … really, really, REALLY hard. And it gets even harder if you want activity vs. Gram-negative bacteria. As the latest proof of this, a paper from GARDP’s Blasco et al. describing use of an

Call for Pull: Swiss Roundtable on Antibiotics

Dear All, To end the week, we have a really lovely paper from the Swiss Roundtable on Antibiotics (a multidisciplinary, non-profit Swiss association). Here are the links you need: The new (25 March 2024) paper entitled “Effective antibiotics for the Swiss health care system: today and in the future.” A prior (7 Feb 2023) paper

Help PASTEUR cross the finish line: Action Alert from IDSA!

Dear All, Today’s news is that the House PASTEUR sponsors (Drew Ferguson [R-GA-3], Scott Peters [D-CA-50], Jake LaTurner [RKS-2] and Mike Levin [D-CA-49]) are urging House leadership to authorize the PASTEUR Act without initially having funding attached. Although this may seem counterintuitive, initial passage as a $0 bill is a solid strategy — it is common

More Newsletters
Subscribe

AMR.Solutions

Using ideas to connect, create, and inspire

Twitter Facebook Linkedin Envelope Instagram Youtube

Supported by the Wellcome Trust

Search

Privacy Policy

Site Map

Scroll to Top